Edition:
United Kingdom

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

67.30EUR
4:35pm BST
Change (% chg)

€-1.20 (-1.75%)
Prev Close
€68.50
Open
€68.12
Day's High
€68.48
Day's Low
€66.72
Volume
1,196,284
Avg. Vol
1,505,918
52-wk High
€80.07
52-wk Low
€58.96

Chart for

About

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes... (more)

Overall

Beta: 0.56
Market Cap(Mil.): €39,028.29
Shares Outstanding(Mil.): 554.54
Dividend: 0.62
Yield (%): 0.88

Financials

  FREG.DE Industry Sector
P/E (TTM): 22.53 28.41 32.75
EPS (TTM): 3.12 -- --
ROI: 9.33 6.42 14.38
ROE: 14.09 10.07 16.07

Fresenius CEO defends canceled Akorn deal

FRANKFURT/BERLIN Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn , saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

18 May 2018

Fresenius CEO defends cancelled Akorn deal

FRANKFURT/BERLIN Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion (3.6 billion pounds) takeover of Akorn , saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

18 May 2018

UPDATE 1-Fresenius CEO defends cancelled Akorn deal

* Expects legal proceedings to conclude in 2019 (Adds details on expenses, comment on provision, analyst)

18 May 2018

Fresenius CEO defends cancelled Akorn deal

FRANKFURT/BERLIN, May 18 Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

18 May 2018

Fresenius sees Akorn lawsuit dragging on into 2019

BERLIN German healthcare group Fresenius SE said on Thursday its legal battle with Akorn over its canceled $4.7 billion takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro.

03 May 2018

Fresenius sees Akorn lawsuit dragging on into 2019

BERLIN German healthcare group Fresenius SE said on Thursday its legal battle with Akorn over its cancelled $4.7 billion (3.5 billion pounds) takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro.

03 May 2018

Fresenius Q1 net income slips 2 pct on strong euro

BERLIN, May 3 German healthcare group Fresenius SE posted a slight decline in quarterly profit on Thursday, hurt by a strong euro, and confirmed its full-year guidance.

03 May 2018

Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

WILMINGTON, Del./NEW YORK German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.

02 May 2018

UPDATE 3-Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

WILMINGTON, Del./NEW YORK, May 2 German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.

02 May 2018

Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

WILMINGTON, Del./NEW YORK German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion (3.5 billion pounds), according to a court filing made public late on Tuesday.

02 May 2018

Earnings vs. Estimates